Regulation of TDP-43 phosphorylation in aging and disease

Insoluble inclusions of phosphorylated TDP-43 occur in disease-affected neurons of most patients with amyotrophic lateral sclerosis (ALS) and about half of patients with frontotemporal lobar degeneration (FTLD-TDP). Phosphorylated TDP-43 potentiates a number of neurotoxic effects including reduced l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:GeroScience 2021-08, Vol.43 (4), p.1605-1614
Hauptverfasser: Eck, Randall J., Kraemer, Brian C., Liachko, Nicole F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1614
container_issue 4
container_start_page 1605
container_title GeroScience
container_volume 43
creator Eck, Randall J.
Kraemer, Brian C.
Liachko, Nicole F.
description Insoluble inclusions of phosphorylated TDP-43 occur in disease-affected neurons of most patients with amyotrophic lateral sclerosis (ALS) and about half of patients with frontotemporal lobar degeneration (FTLD-TDP). Phosphorylated TDP-43 potentiates a number of neurotoxic effects including reduced liquid–liquid phase separation dynamicity, changes in splicing, cytoplasmic mislocalization, and aggregation. Accumulating evidence suggests a balance of kinase and phosphatase activities control TDP-43 phosphorylation. Dysregulation of these processes may lead to an increase in phosphorylated TDP-43, ultimately contributing to neurotoxicity and neurodegeneration in disease. Here we summarize the evolving understanding of major regulators of TDP-43 phosphorylation as well as downstream consequences of their activities. Interventions restoring kinase and phosphatase balance may be a generalizable therapeutic strategy for all TDP-43 proteinopathies including ALS and FTLD-TDP.
doi_str_mv 10.1007/s11357-021-00383-5
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8492835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2579395482</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-4d7e68352a14abf9806eb6e655b423843de652c23fb34238550364dfc70d9dbe3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoVmr_gKcFz9Ekk-wmF0HqJxQUqeeQ3WS3kTZbk67Qf-_WLRUvHoYZZt55ZngRuqDkihJSXCdKQRSYMIoJAQlYHKEzJojCrGBwfKipGKFJSr4knFFKCpCnaAScAFOSnyH15ppuaTa-DVlbZ_O7V8whWy_a1Efc7ic-ZKbxoclMsJn1yZnkztFJbZbJTfZ5jN4f7ufTJzx7eXye3s5wJWixwdwWLpcgmKHclLWSJHdl7nIhSs5AcrB9zSoGdQm7hhAEcm7rqiBW2dLBGN0M3HVXrpytXNhEs9Tr6FcmbnVrvP47CX6hm_ZLS65Yf7gHXO4Bsf3sXNroj7aLof9ZM1EoUIJL1qvYoKpim1J09eECJXrnuB4c173j-sdxvUPDsJR6cWhc_EX_s_UN5viA9Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579395482</pqid></control><display><type>article</type><title>Regulation of TDP-43 phosphorylation in aging and disease</title><source>SpringerNature Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Eck, Randall J. ; Kraemer, Brian C. ; Liachko, Nicole F.</creator><creatorcontrib>Eck, Randall J. ; Kraemer, Brian C. ; Liachko, Nicole F.</creatorcontrib><description>Insoluble inclusions of phosphorylated TDP-43 occur in disease-affected neurons of most patients with amyotrophic lateral sclerosis (ALS) and about half of patients with frontotemporal lobar degeneration (FTLD-TDP). Phosphorylated TDP-43 potentiates a number of neurotoxic effects including reduced liquid–liquid phase separation dynamicity, changes in splicing, cytoplasmic mislocalization, and aggregation. Accumulating evidence suggests a balance of kinase and phosphatase activities control TDP-43 phosphorylation. Dysregulation of these processes may lead to an increase in phosphorylated TDP-43, ultimately contributing to neurotoxicity and neurodegeneration in disease. Here we summarize the evolving understanding of major regulators of TDP-43 phosphorylation as well as downstream consequences of their activities. Interventions restoring kinase and phosphatase balance may be a generalizable therapeutic strategy for all TDP-43 proteinopathies including ALS and FTLD-TDP.</description><identifier>ISSN: 2509-2715</identifier><identifier>EISSN: 2509-2723</identifier><identifier>DOI: 10.1007/s11357-021-00383-5</identifier><identifier>PMID: 34032984</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aging ; Amyotrophic lateral sclerosis ; Biomedical and Life Sciences ; Cell Biology ; Frontotemporal dementia ; Geriatrics/Gerontology ; Life Sciences ; Molecular Medicine ; Neurodegeneration ; Neurotoxicity ; Original ; Original Article ; Phosphatase ; Phosphorylation</subject><ispartof>GeroScience, 2021-08, Vol.43 (4), p.1605-1614</ispartof><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021</rights><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-4d7e68352a14abf9806eb6e655b423843de652c23fb34238550364dfc70d9dbe3</citedby><cites>FETCH-LOGICAL-c517t-4d7e68352a14abf9806eb6e655b423843de652c23fb34238550364dfc70d9dbe3</cites><orcidid>0000-0003-1250-3871</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492835/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492835/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids></links><search><creatorcontrib>Eck, Randall J.</creatorcontrib><creatorcontrib>Kraemer, Brian C.</creatorcontrib><creatorcontrib>Liachko, Nicole F.</creatorcontrib><title>Regulation of TDP-43 phosphorylation in aging and disease</title><title>GeroScience</title><addtitle>GeroScience</addtitle><description>Insoluble inclusions of phosphorylated TDP-43 occur in disease-affected neurons of most patients with amyotrophic lateral sclerosis (ALS) and about half of patients with frontotemporal lobar degeneration (FTLD-TDP). Phosphorylated TDP-43 potentiates a number of neurotoxic effects including reduced liquid–liquid phase separation dynamicity, changes in splicing, cytoplasmic mislocalization, and aggregation. Accumulating evidence suggests a balance of kinase and phosphatase activities control TDP-43 phosphorylation. Dysregulation of these processes may lead to an increase in phosphorylated TDP-43, ultimately contributing to neurotoxicity and neurodegeneration in disease. Here we summarize the evolving understanding of major regulators of TDP-43 phosphorylation as well as downstream consequences of their activities. Interventions restoring kinase and phosphatase balance may be a generalizable therapeutic strategy for all TDP-43 proteinopathies including ALS and FTLD-TDP.</description><subject>Aging</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Biomedical and Life Sciences</subject><subject>Cell Biology</subject><subject>Frontotemporal dementia</subject><subject>Geriatrics/Gerontology</subject><subject>Life Sciences</subject><subject>Molecular Medicine</subject><subject>Neurodegeneration</subject><subject>Neurotoxicity</subject><subject>Original</subject><subject>Original Article</subject><subject>Phosphatase</subject><subject>Phosphorylation</subject><issn>2509-2715</issn><issn>2509-2723</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kE1LAzEQhoMoVmr_gKcFz9Ekk-wmF0HqJxQUqeeQ3WS3kTZbk67Qf-_WLRUvHoYZZt55ZngRuqDkihJSXCdKQRSYMIoJAQlYHKEzJojCrGBwfKipGKFJSr4knFFKCpCnaAScAFOSnyH15ppuaTa-DVlbZ_O7V8whWy_a1Efc7ic-ZKbxoclMsJn1yZnkztFJbZbJTfZ5jN4f7ufTJzx7eXye3s5wJWixwdwWLpcgmKHclLWSJHdl7nIhSs5AcrB9zSoGdQm7hhAEcm7rqiBW2dLBGN0M3HVXrpytXNhEs9Tr6FcmbnVrvP47CX6hm_ZLS65Yf7gHXO4Bsf3sXNroj7aLof9ZM1EoUIJL1qvYoKpim1J09eECJXrnuB4c173j-sdxvUPDsJR6cWhc_EX_s_UN5viA9Q</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Eck, Randall J.</creator><creator>Kraemer, Brian C.</creator><creator>Liachko, Nicole F.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1250-3871</orcidid></search><sort><creationdate>20210801</creationdate><title>Regulation of TDP-43 phosphorylation in aging and disease</title><author>Eck, Randall J. ; Kraemer, Brian C. ; Liachko, Nicole F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-4d7e68352a14abf9806eb6e655b423843de652c23fb34238550364dfc70d9dbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aging</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Biomedical and Life Sciences</topic><topic>Cell Biology</topic><topic>Frontotemporal dementia</topic><topic>Geriatrics/Gerontology</topic><topic>Life Sciences</topic><topic>Molecular Medicine</topic><topic>Neurodegeneration</topic><topic>Neurotoxicity</topic><topic>Original</topic><topic>Original Article</topic><topic>Phosphatase</topic><topic>Phosphorylation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eck, Randall J.</creatorcontrib><creatorcontrib>Kraemer, Brian C.</creatorcontrib><creatorcontrib>Liachko, Nicole F.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>GeroScience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eck, Randall J.</au><au>Kraemer, Brian C.</au><au>Liachko, Nicole F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulation of TDP-43 phosphorylation in aging and disease</atitle><jtitle>GeroScience</jtitle><stitle>GeroScience</stitle><date>2021-08-01</date><risdate>2021</risdate><volume>43</volume><issue>4</issue><spage>1605</spage><epage>1614</epage><pages>1605-1614</pages><issn>2509-2715</issn><eissn>2509-2723</eissn><abstract>Insoluble inclusions of phosphorylated TDP-43 occur in disease-affected neurons of most patients with amyotrophic lateral sclerosis (ALS) and about half of patients with frontotemporal lobar degeneration (FTLD-TDP). Phosphorylated TDP-43 potentiates a number of neurotoxic effects including reduced liquid–liquid phase separation dynamicity, changes in splicing, cytoplasmic mislocalization, and aggregation. Accumulating evidence suggests a balance of kinase and phosphatase activities control TDP-43 phosphorylation. Dysregulation of these processes may lead to an increase in phosphorylated TDP-43, ultimately contributing to neurotoxicity and neurodegeneration in disease. Here we summarize the evolving understanding of major regulators of TDP-43 phosphorylation as well as downstream consequences of their activities. Interventions restoring kinase and phosphatase balance may be a generalizable therapeutic strategy for all TDP-43 proteinopathies including ALS and FTLD-TDP.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>34032984</pmid><doi>10.1007/s11357-021-00383-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-1250-3871</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2509-2715
ispartof GeroScience, 2021-08, Vol.43 (4), p.1605-1614
issn 2509-2715
2509-2723
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8492835
source SpringerNature Journals; PubMed Central; Alma/SFX Local Collection
subjects Aging
Amyotrophic lateral sclerosis
Biomedical and Life Sciences
Cell Biology
Frontotemporal dementia
Geriatrics/Gerontology
Life Sciences
Molecular Medicine
Neurodegeneration
Neurotoxicity
Original
Original Article
Phosphatase
Phosphorylation
title Regulation of TDP-43 phosphorylation in aging and disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T04%3A27%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulation%20of%20TDP-43%20phosphorylation%20in%20aging%20and%20disease&rft.jtitle=GeroScience&rft.au=Eck,%20Randall%20J.&rft.date=2021-08-01&rft.volume=43&rft.issue=4&rft.spage=1605&rft.epage=1614&rft.pages=1605-1614&rft.issn=2509-2715&rft.eissn=2509-2723&rft_id=info:doi/10.1007/s11357-021-00383-5&rft_dat=%3Cproquest_pubme%3E2579395482%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579395482&rft_id=info:pmid/34032984&rfr_iscdi=true